After removing articles lacking full text, articles that were not relevant to the aim, and those that did not conform to the predefined inclusion criteria, three articles remained for analysis (Fig
Emerging dual agonists, such as survodutide and cotadutide, which target GLP-1 and glucagon receptors, are being explored for treating metabolically associated fatty liver disease and may also address fatty kidney, a key factor in CKD related to visceral obesity [48]
The best results occur when treatment is individualized and combined with nutrition, activity, sleep, stress management, and ongoing medical support
Nucleic Acids Res 2003, 31 (1), 319321
Women of reproductive age are at particular risk
In turn, you grant us a non-exclusive, royalty-free license to use any content you post on the Site for any purpose, subject to the express provisions of these Terms